INGN Inogen Inc
Orthopedic, Prosthetic & Surgical Appliances & Supplies · Nasdaq · SEC CIK 1294133 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.7%
TTM net income YoY-39.7%
TTM EPS YoY-32.0%
Revenue 3-yr CAGR5.0%
Net income 3-yr CAGR—
Margins
Gross margin39.6%
Operating margin-10.4%
Net margin-9.3%
FCF margin-3.0%
EBITDA margin-4.2%
Returns
ROE-20.0%
ROA-12.4%
ROIC (approx.)-37.5%
Asset turnover1.33x
Leverage & solvency
Liabilities / assets40.7%
Debt / equity0.00x
Current ratio2.96x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.26x
Accruals ratio-9.2%
Payout ratio—
Capex / revenue0.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $348.67M | $335.70M | $315.66M | $377.24M | $358.00M |
| Cost of revenue | $194.40M | $180.96M | $188.96M | $223.71M | $181.52M |
| Gross profit | $154.26M | $154.74M | $126.70M | $153.53M | $176.48M |
| R&D expense | $19.40M | $21.61M | $20.84M | $21.94M | $16.58M |
| SG&A expense | $67.38M | $72.58M | $75.26M | $43.91M | $37.85M |
| Operating income | -$30.21M | -$42.52M | -$109.39M | -$85.24M | $9.24M |
| Pretax income | -$23.38M | -$36.48M | -$102.34M | -$83.27M | $8.66M |
| Income tax | -$632,000 | -$588,000 | $105,000 | $504,000 | $14.99M |
| Net income | -$22.75M | -$35.89M | -$102.45M | -$83.77M | -$6.33M |
| EBITDA | -$9.55M | -$21.51M | -$91.23M | -$61.73M | $30.87M |
| EPS (basic) | -0.86 | -1.52 | -4.42 | -3.67 | -0.28 |
| EPS (diluted) | -0.86 | -1.52 | -4.42 | -3.67 | -0.28 |
| Weighted avg. shares (diluted) | 26.60M | 23.65M | 23.18M | 22.85M | 22.49M |
| Balance sheet | |||||
| Cash & equivalents | $103.73M | $113.80M | $125.49M | $187.01M | $235.52M |
| Short-term investments | $15.85M | $0 | $2.98M | — | $9.99M |
| Receivables | $34.14M | $29.56M | $42.24M | $62.73M | $24.45M |
| Inventory | $25.97M | $24.81M | $21.84M | $34.09M | $31.87M |
| Current assets | $224.60M | $185.45M | $207.07M | $304.64M | $329.19M |
| PP&E, net | $10.06M | $44.40M | $50.32M | $43.27M | $38.93M |
| Goodwill | $10.70M | $9.46M | $10.06M | $32.85M | $32.98M |
| Intangibles | $30.76M | $30.49M | $34.59M | $177,000 | $60.15M |
| Total assets | $298.62M | $296.19M | $326.19M | $405.04M | $489.51M |
| Current liabilities | $63.53M | $76.69M | $72.50M | $65.35M | $61.51M |
| Total liabilities | $106.39M | $122.33M | $121.38M | $107.64M | $119.29M |
| Shareholders' equity | $192.23M | $173.86M | $204.81M | $297.41M | $370.23M |
| Shares outstanding | 27.23M | 23.90M | 23.32M | 22.94M | 22.73M |
| Cash flow statement | |||||
| Operating cash flow | -$11.22M | $5.91M | -$3.23M | -$37.53M | $23.63M |
| Capital expenditure | $2.52M | $3.36M | $5.22M | $3.34M | $5.48M |
| Free cash flow | -$13.74M | $2.55M | -$8.45M | -$40.87M | $18.15M |
| Investing cash flow | -$26.21M | -$13.97M | -$59.31M | -$10.88M | -$14.64M |
| Financing cash flow | $24.18M | $265,000 | $960,000 | $380,000 | $15.00M |
| Depreciation & amortization | $20.66M | $21.00M | $18.15M | $23.51M | $21.63M |
| Stock-based compensation | $8.01M | $7.40M | $7.43M | $12.28M | $10.94M |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.